Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

I am medical oncologist dedicated to the care of patients with genitourinary malignancies. My clinical and research focus is on the management of renal cell carcinoma (RCC). I have completed Medical Oncology Higher Specialist Training with Royal College of Physicians in Ireland and subsequently completed Advanced Medical Oncology Fellowship at the Memorial Sloan Kettering Cancer Center in New York. Dr. Ged is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Arvin K. George, MD, is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers, with particular sub-specialization in kidney and prostate cancers. His clinical interests and expertise are in image-guided therapeutics, and minimally-invasive ablative/surgical techniques for prostate and kidney cancer. These include laparoscopic and robotic surgery, in addition to cryoablation, high-intensity focused ultrasound ablation, nanoparticle directed laser ablation, laser interstitial thermal therapy, and bipolar radiofrequency ablation. Dr. George obtained his medical degree from the Royal College of Surgeons in Ireland, followed by a urology residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his endourology/minimally-invasive and robotic surgery fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute, National Institutes of Health. He then joined the clinical facility at the University of Michigan, Ann Arbor, where he directed the Prostate Cancer Programs from 2019 through 2023. Dr. George participates extensively in the discovery of urologic science and evaluation of urologic care and has co-authored over 80 peer reviewed publications. Additionally, he has authored 11 chapters in medical education books. Dr. George sees patients in clinic throughout the Baltimore region and also is available for virtual appointments for patients in Maryland, Washington D.C., New York and Michigan. Dr. George is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Ahmed Ghazi is an associate professor of urology at the Johns Hopkins University School of Medicine. He is the Director of Surgical Simulation Training and the Division of Minimally Invasive and Robotic Surgery within the Johns Hopkins Brady Urological Institute. Dr. Ghazi specializes in urologic surgical oncology using the latest techniques of minimally invasive surgery for prostate, kidney, bladder, ureteral and other genitourinary organ cancers. He also as specializes in minimal invasive treatment of complex stones of the urinary tract. Dr. Ghazi is a pioneer in the field of patient-specific surgical simulation, which has applications for training future surgeons as well as improving outcomes for patients through individualized modeling. When planning for a complex surgery, Dr. Ghazi constructs 3D models of the patient’s anatomy in order to plan and rehearse surgery prior to the actual surgery. These models span from digital renderings to tangible models used to practice the critical components of your surgery. Dr. Ghazi received his medical degree from Cairo University in Egypt in 2000, where he also completed his surgery training and urology residency. From there, Dr. Ghazi completed a laparoscopic fellowship in Paris, France in 2008, followed by a second laparoscopic fellowship in Austria in 2009. While practicing in Europe, Dr. Ghazi was accepted to the European Board of Urology. Dr. Ghazi continued his training at the University of Rochester, New York through a two-year fellowship in the robotic treatment of various urologic cancers. He then joined the staff at the urology department of University of Rochester in 2012 where he continued to practice until joining Johns Hopkins Medicine. Dr. Ghazi believes in a reciprocal relationship between innovation, surgery & research where each informs and strengthens the others. He strives to adopt innovative surgical technologies that are evidence-based, benefit his patients and translate directly to improved patient outcomes. Dr. Ghazi is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Kidney Stones, Boils, Prostatectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Arun Rai, M.D., M.B.A., M.S., is a urologist who specializes in minimally invasive surgery and endourology and has extensive training to treat patients with adrenal cancer, kidney cancer, ureteral cancer and prostate cancer. In addition, he also specializes in treating patients with BPH, kidney stones and bladder stones. Dr. Rai earned both his undergraduate and medical degrees through the highly selective seven-year accelerated medical education program at Boston University School of Medicine. Dr. Rai went on to complete a general surgery internship at Baylor College of Medicine, where he then also completed his urology residency. Dr. Rai continued his training at the Northwell Health’s Smith Institute for Urology by completing a fellowship in Endourology and Minimally Invasive Surgery. During this time, he also received a dual MBA/MS in Healthcare Leadership Weill Cornell Graduate School of Medical Sciences and Cornell University. In addition to caring for patients, Dr. Rai serves as Clinical Director for the Brady Urological Institute's Quantitative Data Sciences division. His research focuses on developing the next generation of surgical technology, focusing on artificial intelligence and machine learning for optimizing clinical care. He strongly believes that surgeons should have an active role in the development of the next generation of tools for the optimal treatment of patients. He has authored several publications, with topics including patient safety in the operating room, long-term outcomes of subcapsular renal hematoma, pelvi-ureteric junction obstruction and featured in journals such as Urology and the Journal of Endourology. Dr. Rai is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Kidney Stones, Horseshoe Kidney, Boils, Ureteroscopy, and Lithotripsy.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Naren Nimmagadda, M.D., is an assistant professor of urology at the Johns Hopkins University School of Medicine. He treats a wide range of benign and malignant urological conditions. As a fellowship trained urologist in endourologic and laparoscopic surgery, his practice focuses on treated voiding issues related to BPH through Holmium Laser Enucleation of the Prostate (HoLEP), an alternative to transurethral resection of the prostate (TURP). Dr. Nimmagadda also specializes in treating kidney, ureteral and bladder stones via shockwave lithotripsy, endoscopic and percutaneous techniques. Dr. Nimmagadda is the Endourology, Minimally Invasive Urology Fellowship Program Director. Dr. Nimmagadda attended medical school at the University of Maryland School of Medicine. Following medical school, Dr. Nimmagadda completed a general surgery internship and residency in urology at Massachusetts General Hospital. He then completed a fellowship in endourology and laparoscopic surgery at Vanderbilt University Medical Center. Following graduation, Dr. Nimmagadda served on the Vanderbilt University Medical Center’s Department of Urology faculty as an instructor. Dr. Nimmagadda has research interest in the intersection of urology and technological innovation. Dr. Nimmagadda is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Kidney Stones, Enlarged Prostate (BPH), UPJ Obstruction, Ureteroscopy, and Lithotripsy.

Dr. Herati is a urologist with fellowship training in male infertility and andrology. He has specialized training to perform complex reconstructions of the reproductive system, including vasectomy reversal with vasovasostomy and vasoepididymostomy. Additionally, he has an interest in treating patients with chronic prostatitis and pelvic pain, as well as patients experiencing low testosterone, erectile dysfunction, Peyronie’s disease and benign prostatic hyperplasia (BPH). Of note, he has the ability to perform fertility treatments on patients who have experienced spinal cord injuries using nonsurgical methods of sperm extraction. Dr. Herati believes in an individualized approach to care that addresses the whole patient. He invests significant time into building a rapport with his patients so that they feel comfortable opening up about these issues, allowing him to accurately identify and manage each patient’s needs. His research interests include decoding the genetic basis of male infertility, investigating the impact of referred pain from peripheral nerves to the bladder, and characterizing the effects of low testosterone on prostate inflammation and PSA screening. Dr. Herati sees patients at both the Johns Hopkins Hospital and The Johns Hopkins Bayview Medical Center. Videos Amin Herati, M.D.Urologist. Dr. Herati is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Enlarged Prostate (BPH), Varicocele, Hypogonadism, Nephrectomy, and Prostatectomy.

Dr. Elias is a medical oncologist and physician scientist specializing in the treatment of genitourinary (kidney, prostate, bladder) cancers. Dr. Elias received his medical degree from the University of Miami Medical School. He completed his residency in Internal Medicine at the University of Texas Southwestern in Dallas, TX. He went on to complete a fellowship in Medical Oncology at Johns Hopkins in Baltimore MD. Dr. Elias’ laboratory is focused on the development of biomarkers and novel therapeutics for genitourinary malignancies. Dr. Elias is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Testicular Yolk Sac Tumor, Testicular Cancer, Acute Promyelocytic Leukemia, and Nephrectomy.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Dr. Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical and research interests focus on medical imaging with specific emphasis on three-dimensional (3D) imaging and computed tomography (CT). Dr. Fishman received his B.S. in 1973 and M.D. in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, he completed a fellowship in CT at Johns Hopkins in 1980 and joined the Johns Hopkins faculty in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology. He is a leader in the development of 3D imaging and rendering, including its impacts on and uses in patient care and management. He was involved from the beginning in the development of 3D imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. His team is consistently at the forefront of research and development of new visualization and post-processing techniques and technologies. Dr. Fishman's extensive body of work in CT has resulted in over 1,000 peer-reviewed publications, and he is the author or co-author of 10 textbooks. He is the recipient of three prestigious Aunt Minnie Awards, honoring his outstanding contributions as both an educator and researcher. In 2007, he was named by Medical Imaging Magazine as the Top Radiologist in the Nation. He is a member of editorial boards for more than 35 journals, an active member of several professional radiology associations and is a past-president of the Society of Body CT/MR. Dr. Fishman is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Cavernous Lymphangioma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.

Dr. Misop Han is David Hall McConnell Professor of Urology and Oncology at the Johns Hopkins School of Medicine. Dr. Han is a urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. He specializes in robotic nerve-sparing prostatectomy and robotic nephrectomy. Dr. Han received his undergraduate and medical degrees at Johns Hopkins. After an internship in surgery and residency in urology, also at Johns Hopkins, he worked as faculty at Northwestern University and Hospital in Chicago, Illinois. In 2006, he joined the Johns Hopkins faculty. His research interests include the outcome of radical prostatectomy, medical robotics and prediction modeling (what happens to men following surgery for prostate cancer). He has published extensively in these subjects and has received international and national recognition for his research. He is actively involved in several clinical research projects with the database of more than 20,000 men who received surgery for prostate cancer at The Johns Hopkins Hospital. He is a member of the American Urological Association and the American Medical Association. Dr. Han is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Ureterocele, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Kelvin K. Hong is an Associate Professor and Executive Vice Chair of Radiology within the Johns Hopkins Department of Radiology. A specialist in interventional and vascular radiology, Dr. Hong serves as the Medical Director of the Johns Hopkins Interventional Radiology Center. Dr. Hong earned his medical degree from South Africa’s University Of Witwatersrand Medical School in Parktown. He completed a radiology residency at Parktown West’s College of Medicine/Radiology, as well as a cardiovascular/interventional radiology fellowship and diagnostic radiology residency at The Johns Hopkins Hospital. His areas of clinical expertise include bone, liver and soft-tissue tumors; chronic total occlusions; claudication; deep venous thrombosis; lung, esophageal and kidney cancer; peripheral arterial/vascular disease; renal artery/vascular disease; uterine fibroid tumors; varicocele; and vascular malformations and venous thromboembolism. Dr. Hong performs procedures that include radiofrequency ablation for lung, liver, kidney and bone lesions; transcatheter arterial chemoembolization for liver cancer; lower-extremity angioplasty and stenting; visceral angioplasty and stenting; embolization of uterine fibroid tumors; cryoablation for pain control; and percutaneous laser ablation of varicose veins. Dr. Hong served as editor for the book Percutaneous Tumor Ablation and contributed to Interventional Oncology: Principles and Practice. Dr. Hong is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Fibrolamellar Carcinoma, Bile Duct Obstruction, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.